trending Market Intelligence /marketintelligence/en/news-insights/trending/EVz3rmfJ9kd3zoj8LDYyMw2 content esgSubNav
In This List

AngioDynamics acquires Israel's Eximo Medical for $46M upfront

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AngioDynamics acquires Israel's Eximo Medical for $46M upfront

AngioDynamics Inc. acquired Israel-based Eximo Medical Ltd. for $46 million upfront, with up to $20 million tied to the completion of certain milestones.

As part of the deal, Latham, N.Y.-based AngioDynamics will also be acquiring Eximo's proprietary 355nm wavelength laser atherectomy technology, which has received 510(k) clearance by the U.S. Food and Drug Administration for the treatment of peripheral artery disease, or PAD.

The system can treat PAD lesions ⁠— located above or below the knee ⁠— ranging from soft plaque to severely calcified, and is indicated to provide treatment for In-Stent Restenosis, which is the gradual re-narrowing of the artery after a blockage has been previously treated with a stent, AngioDynamics said in an Oct. 3 press release.

AngioDynamics is a medical device company providing minimally invasive equipment to healthcare professionals for treating vascular diseases and cancer.